165 related articles for article (PubMed ID: 31349094)
1. Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy.
Lee J; Le QV; Yang G; Oh YK
Biomaterials; 2019 Oct; 218():119359. PubMed ID: 31349094
[TBL] [Abstract][Full Text] [Related]
2. Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy.
Wu H; Zhang L; Zhu Z; Ding C; Chen S; Liu R; Fan H; Chen Y; Li H
Drug Deliv; 2021 Dec; 28(1):1166-1178. PubMed ID: 34121564
[TBL] [Abstract][Full Text] [Related]
3. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.
Xu Y; Chen C; Guo Y; Hu S; Sun Z
Front Immunol; 2022; 13():848327. PubMed ID: 35300341
[TBL] [Abstract][Full Text] [Related]
4. Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration.
Luo B; Zhan Y; Luo M; Dong H; Liu J; Lin Y; Zhang J; Wang G; Verhoeyen E; Zhang Y; Zhang H
Cell Death Dis; 2020 Nov; 11(11):973. PubMed ID: 33184267
[TBL] [Abstract][Full Text] [Related]
5. Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy.
Klepsch V; Pommermayr M; Humer D; Brigo N; Hermann-Kleiter N; Baier G
Cell Commun Signal; 2020 Jan; 18(1):8. PubMed ID: 31937317
[TBL] [Abstract][Full Text] [Related]
6. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
7. Delivering Cas9/sgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient 'hit-and-run' genome editing.
Lyu P; Javidi-Parsijani P; Atala A; Lu B
Nucleic Acids Res; 2019 Sep; 47(17):e99. PubMed ID: 31299082
[TBL] [Abstract][Full Text] [Related]
8. Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy.
Zhang C; Peng Y; Hublitz P; Zhang H; Dong T
Sci Rep; 2018 Apr; 8(1):5549. PubMed ID: 29615718
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
[TBL] [Abstract][Full Text] [Related]
10. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
11. Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy.
Lu Q; Chen R; Du S; Chen C; Pan Y; Luan X; Yang J; Zeng F; He B; Han X; Song Y
Biomaterials; 2022 Dec; 291():121871. PubMed ID: 36323073
[TBL] [Abstract][Full Text] [Related]
12. Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer.
Zhang W; Shi L; Zhao Z; Du P; Ye X; Li D; Cai Z; Han J; Cai J
Cancer Chemother Pharmacol; 2019 May; 83(5):911-920. PubMed ID: 30848330
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.
Su S; Hu B; Shao J; Shen B; Du J; Du Y; Zhou J; Yu L; Zhang L; Chen F; Sha H; Cheng L; Meng F; Zou Z; Huang X; Liu B
Sci Rep; 2016 Jan; 6():20070. PubMed ID: 26818188
[TBL] [Abstract][Full Text] [Related]
14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
15. HSP70-Promoter-Driven CRISPR/Cas9 System Activated by Reactive Oxygen Species for Multifaceted Anticancer Immune Response and Potentiated Immunotherapy.
Zhao L; Li D; Zhang Y; Huang Q; Zhang Z; Chen C; Xu CF; Chu X; Zhang Y; Yang X
ACS Nano; 2022 Sep; 16(9):13821-13833. PubMed ID: 35993350
[TBL] [Abstract][Full Text] [Related]
16. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
Song Y; Li Z; Xue W; Zhang M
Immunotherapy; 2019 Apr; 11(6):515-529. PubMed ID: 30860441
[TBL] [Abstract][Full Text] [Related]
17. Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-Associated Endonuclease Cas9-Mediated Homology-Independent Integration for Generating Quality Control Materials for Clinical Molecular Genetic Testing.
Lin G; Zhang K; Peng R; Han Y; Xie J; Li J
J Mol Diagn; 2018 May; 20(3):373-380. PubMed ID: 29680088
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
19. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
[TBL] [Abstract][Full Text] [Related]
20.
Kim J; Francis DM; Thomas SN
Nanomaterials (Basel); 2021 Feb; 11(2):. PubMed ID: 33673289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
